Fatal Breakthrough COVID-19 after Bivalent Booster Dose

70-year-old female with pre-existing conditions (systolic heart failure, A-fib, chronic kidney disease, diabetes, renal disease, ischemic cardiomyopathy, proteinuria, secondary hyperparathyroidism of renal origin, with defibrillator and on warfarin) received her 5th dose of Moderna vaccine (updated bivalent booster) in September 2022. Two months later she tested positive for COVID-19, was admitted to the hospital and died on the 8th day after symptom onset, despite treatment. 

76-year-old male with a history of diabetes and coronary artery disease received five doses of the Pfizer vaccine (Dose 1 in January 2021, Dose 2 in February 2021, Dose 3 in October 2021, Dose 4 in April 2022 and Dose 5 (bivalent) on 10/26/22). On 11/2/22, seven (7) days after receiving the Pfizer bivalent booster, patient tested positive for COVID via PCR after being admitted to hospital for unspecified reasons. The patient died on 11/3/22 (8 days after booster) and the cause of death is listed as multiorgan failure (primary), cardiogenic shock (secondary), acute myocardial infarction (secondary), and coronary artery disease (secondary). 

87-year-old male had received all 5 doses of Moderna COVID vaccine (primary series, 2 regular boosters, and bivalent booster) & presented to the Emergency Department from his outpatient clinic visit 1.5 months after his last dose for workup of hypotension. He also had a cough, & tested positive for COVID, but that was not his chief complaint nor the reason of why he was admitted. He passed away from Pulseless Electrical Activity (PEA) arrest 6 days later.

71-year-old male with preexisting conditions (lung cancer and kidney failure) was vaccinated 5 times with the Pfizer BNT162b2 vaccine, having received it in February and August 2021, March 2022 and, the 5th dose, in August 2022. He was hospitalized one month later for multiple reasons, including small bowel perforation, shock, hypoxic respiratory failure, multiple metastasized adenocarcinoma of the lung, acute renal failure, and a-Fib. He was transferred to a hospice facility where he tested negative for COVID-19 on 09/15/2022 but then positive on 09/25/2022 and 09/26/2022. He died on 10/04/2022.

75-year-old female with preexisting conditions (Chronic Inflammatory Demyelinating Polyneuritis, Hypertension, Neurogenic Bladder, Hyperlipidemia, Osteoarthritis, Carcinoma of the Breast) received 5 doses of Moderna vaccine. She tested positive for COVID-19 5 month after the 5th dose and died 18 days after her positive test. 


REFERENCES

Case 2504415 from the VAERS Database (medalerts.org)

Case 2509441 from the VAERS Database (medalerts.org)

Case 2514132 from the VAERS Database (medalerts.org)

Case 2522074 from the VAERS Database (medalerts.org)

Case 2523225 from the VAERS Database (medalerts.org)

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more